<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>surprise &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/surprise/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Sun, 09 Feb 2025 06:30:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>surprise &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Confirm the shares by 22% of sales, surprise gain through the holiday</title>
		<link>https://bloggingthree.soflytech.com/2025/02/confirm-the-shares-by-22-of-sales-surprise-gain-through-the-holiday/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sun, 09 Feb 2025 06:30:32 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[confirm]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[holiday]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[surprise]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=24230</guid>

					<description><![CDATA[Confirm The shares rose by 22.8%on Friday after purchase, the later company company within the second quarter for the sales forecast of Wall Street and achieved a surprise gain in a powerful shopping period. The result was 23 cents per share in front of the analyst surveyed by LSEG, which was expected by the analysts [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Confirm<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    The shares rose by 22.8%on Friday after purchase, the later company company within the second quarter for the sales forecast of Wall Street and achieved a surprise gain in a powerful shopping period.</p>
<p>The result was 23 cents per share in front of the analyst surveyed by LSEG, which was expected by the analysts surveyed by LSEG. The company also recorded sales of $ 866 million and recorded growth of 47%in comparison with the previous yr. The analysts forecast revenue of $ 807 million.</p>
<p>&#8220;We have exceeded the adjusted operating result, which our profitability metric, which we lead,&#8221; in comparison with CNBC, Chief Financial Officer Rob O&#39;Hare.</p>
</div>
<div class="group">
<p>The gross volume of products, a continuously used metric within the room that shows the entire value of transactions, achieved $ 10.1 billion and exceeded a street account estimate of 9.64 billion US dollars. It was the primary time that the number passed $ 10 billion and was reflected in 35% growth in comparison with the previous yr.</p>
<p>In a letter to the shareholders, the corporate gave a big a part of growth for profits in its general business with goods and consumer electronics business through the shopping season.</p>
<p>Affirm said that it remains to be planning to achieve the GAAP redematability until the top of its fourth quarter. Over the present period, the corporate expects sales between 755 and 785 million US dollars. Active users who used the corporate&#39;s products rose by 23% to 21 million from a previous yr.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108027302-1724954436051-108027302-1724954167573-gettyimages-995761246-775159596.jpeg?v=1730312684&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>The Syrian government falls in a surprise end to the Assad family&#039;s 50-year rule</title>
		<link>https://bloggingthree.soflytech.com/2024/12/the-syrian-government-falls-in-a-surprise-end-to-the-assad-familys-50-year-rule/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sun, 08 Dec 2024 23:34:42 +0000</pubDate>
				<category><![CDATA[Politics]]></category>
		<category><![CDATA[50year]]></category>
		<category><![CDATA[Assad]]></category>
		<category><![CDATA[falls]]></category>
		<category><![CDATA[family39s]]></category>
		<category><![CDATA[government]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[surprise]]></category>
		<category><![CDATA[Syrian]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=20559</guid>

					<description><![CDATA[World News BEIRUT (AP) — The Syrian government fell early Sunday, bringing a surprise end to the Assad family&#39;s 50-year rule, after a sudden rebel offensive advanced across government-held territory and entered the capital inside 10 days. Syrian state television broadcast a video statement from a bunch of men saying President Bashar al-Assad had been [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.boston.com/wp-content/uploads/2024/12/AP24343438170623-6755c7080415d-850x638.jpg" /></p>
<div id="">
<header class="m-article-header m-article-header--standard">
												<span id="article-header-primary-term"></p>
<p>								World News<br />
							</span></p>
</header>
<p>BEIRUT (AP) — The Syrian government fell early Sunday, bringing a surprise end to the Assad family&#39;s 50-year rule, after a sudden rebel offensive advanced across government-held territory and entered the capital inside 10 days.</p>
<p>Syrian state television broadcast a video statement from a bunch of men saying President Bashar al-Assad had been overthrown and that each one prison inmates had been released.</p>
<p>The man who read the statement said the opposition group Operations Room to Conquer Damascus called on all opposition fighters and residents to preserve the state institutions of the &#8220;free Syrian state.&#8221;</p>
<p>The statement got here hours after the pinnacle of a Syrian opposition war monitor said Assad had left the country for an unknown location, fleeing insurgents who said that they had entered Damascus after the remarkably rapid advance through the country.</p>
<p>Syrian Prime Minister Mohammed Ghazi Jalali said the federal government was able to &#8220;extend its hand&#8221; to the opposition and hand over its duties to an interim government.</p>
<p>“I am in my house and I have not left it, and that is because I belong to this country,” Jalili said in a video statement. He said he would go to his office within the morning to proceed his work and urged Syrian residents to not deface public property.</p>
<p>He didn&#8217;t address reports that Assad had fled.</p>
<p>Rami Abdurrahman of the Syrian Observatory for Human Rights told the Associated Press that Assad took a flight from Damascus on Sunday.</p>
<p>Iranian state television, Assad&#39;s primary supporter throughout the war years in Syria, reported that Assad had left the capital. Qatari news channel Al Jazeera was quoted as providing the knowledge without elaborating.</p>
<p>There was no immediate comment from the Syrian government.</p>
<p>As day broke over Damascus, crowds gathered to hope in town&#39;s mosques and have a good time in its squares, chanting &#8220;God is great.&#8221; People also chanted anti-Assad slogans and honked their horns. In some areas, celebratory shots were fired.</p>
<p>Soldiers and police abandoned their posts and fled, and looters broke into the Defense Ministry headquarters.</p>
<p>“My feelings are indescribable,” said Omar Daher, a 29-year-old lawyer. “After the fear in which he (Assad) and his father made us live for many years, and the panic and state of terror in which I lived, I cannot believe it.”</p>
<p>Daher said his father was killed by security forces and his brother was in custody, but his fate was unknown. Assad “is a criminal, a tyrant and a dog,” he said.</p>
<p>“Damned be his soul and the soul of the entire Assad family,” said Ghazal al-Sharif, one other reveler in central Damascus. “It is the prayer of every oppressed person and God has answered it today. We thought we would never see it, but thank God we did.”</p>
<p>The police headquarters within the capital gave the impression to be deserted, the door was open and nobody was outside. An Associated Press journalist captured footage of an abandoned army checkpoint where uniforms lay on the bottom beneath a poster with Assad&#39;s face. Footage broadcast by opposition-affiliated media showed a tank in one in all the capital&#39;s central squares.</p>
<p>It was the primary time opposition forces had reached Damascus since 2018, when Syrian troops recaptured areas on the outskirts of the capital after a years-long siege.</p>
<p>Pro-government radio station Sham FM reported that Damascus airport had been evacuated and all flights had been suspended.</p>
<p>The insurgents also announced that that they had entered the notorious Saydnaya military prison north of the capital and “freed” their prisoners there.</p>
<p>The night before, opposition forces had captured the central city of Homs, Syria&#39;s third-largest city, after government troops abandoned it. The city lies at a key junction between the capital Damascus and the Syrian coastal provinces of Latakia and Tartus &#8211; the bottom of the Syrian leader and the positioning of a strategic Russian naval base.</p>
<p>The rebels had already captured the cities of Aleppo and Hama in addition to large parts of the south in a lightning offensive that began on November twenty seventh. Analysts said rebel control of Homs can be a game-changer.</p>
<p>The rebels&#39; entry into Damascus got here after the Syrian army withdrew from much of the southern a part of the country and other areas, including several provincial capitals, remained under the control of opposition fighters.</p>
<p>The advances last week were by far the most important in years by opposition factions led by a bunch that has its origins in al-Qaeda and is designated a terrorist organization by the United States and the United Nations. In their push to topple Assad&#39;s government, the insurgents led by the Hayat Tahrir al-Sham group (HTS) faced little resistance from the Syrian army.</p>
<p>UN special envoy for Syria Geir Pedersen called on Saturday for urgent talks in Geneva to make sure an “orderly political transition”. Speaking to reporters on the annual Doha Forum in Qatar, he said the situation in Syria was changing by the minute. Russian Foreign Minister Sergei Lavrov, whose country is Assad&#39;s primary international backer, said he felt “compassion for the Syrian people.”</p>
<p>In Damascus, people rushed to fill up on supplies. Thousands went to Syria&#39;s border with Lebanon and tried to go away the country. Lebanese border officials closed the primary Masnaa border crossing late Saturday, leaving many individuals waiting.</p>
<p>Many shops within the capital were closed, a resident told The Associated Press, and people still open were running out of staples reminiscent of sugar. Some were selling items for 3 times the traditional price.</p>
<p>The United Nations said it was moving non-critical personnel in a foreign country as a precaution.</p>
<p>Syrian state media denied social media rumors that Assad had left the country, saying he was carrying out his duties in Damascus.</p>
<p>He received little to no help from his allies. Russia is busy with its war in Ukraine. Lebanon&#39;s Hezbollah, which once sent 1000&#8217;s of fighters to support Assad&#39;s forces, has been weakened by years of conflict with Israel. Iran has seen its proxies across the region weakened by regular Israeli airstrikes.</p>
<p>US President-elect Donald Trump posted on social media on Saturday that the United States should avoid military involvement in Syria. Separately, President Joe Biden&#39;s national security adviser said the Biden administration had no intention of intervening there.</p>
<p>Pedersen said a date for talks in Geneva on implementing a 2015 U.N. resolution calling for a Syrian-led political process can be announced later. The resolution calls for the establishment of an interim governing body, followed by the drafting of a brand new structure and at last elections supervised by the United Nations.</p>
<p>Later Saturday, foreign ministers and senior diplomats from eight key countries, including Saudi Arabia, Russia, Egypt, Turkey and Iran, met with Pederson on the sidelines of the Doha summit to debate the situation in Syria.</p>
<p>In a press release, participants reiterated their support for a political solution to the Syrian crisis “that would lead to an end to military activities and protect civilians.”</p>
<p>An insurgent commander, Hassan Abdul-Ghani, posted on the messaging app Telegram that opposition forces had begun the &#8220;final phase&#8221; of their offensive by encircling Damascus.</p>
<p>HTS controls much of northwest Syria and established a “salvation government” in 2017 to administer day-to-day affairs within the region. In recent years, HTS leader Abu Mohammed al-Golani has sought to reshape the group&#39;s image by cutting ties with al-Qaeda, abandoning hardline officials and embracing pluralism and non secular tolerance.</p>
<p>The shock offensive began on November twenty seventh. Gunmen captured the northern city of Aleppo, Syria&#39;s largest city, and the central city of Hama, the country&#39;s fourth largest city.</p>
<p>Since the conflict began in March 2011, the Syrian government has described armed opposition members as terrorists.</p>
<p>Qatar&#39;s top diplomat, Sheikh Mohammed bin Abdulrahman Al Thani, criticized Assad for failing to reap the benefits of the lull in fighting lately to deal with the country&#39;s underlying problems. “Assad has not taken advantage of this opportunity to engage with his people and restore relations with them,” he said.</p>
</p></div>
<p><script>
		var consent="grant";
		/* The above code is parsing the JSON data from the local storage and storing it in a variable. */
					const onetrustStorageConsent = JSON.parse(localStorage.getItem( 'consent_one_trust_bdc' ) );
			if ( ( onetrustStorageConsent !== null ) ) {
				/* Checking to see if the user has consented to the use of cookies.
				* If they have not, it is deleting the cookie.
				* This will comment for now, until further notice.
				*/
				//if ( onetrustStorageConsent.C0002 === false ) {
				//	document.cookie="_fbp=;expires=Thu, 01 Jan 2010 00:00:00 UTC; path=/; domain=.boston.com";
				//}
				/* Checking if the user has given consent for the cookie C0002.
				* If the user has given consent, the variable consent will be set to 'grant'.
				* If the user has not given consent,the variable consent will be set to 'revoke'.
				* Documentation https://developers.facebook.com/docs/meta-pixel/implementation/gdpr
				*/
				if ( onetrustStorageConsent.C0002 !== true ) {
					consent="revoke";
				}
			}
				!function(f,b,e,v,n,t,s)
		{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
		n.callMethod.apply(n,arguments):n.queue.push(arguments)};
		if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
		n.queue=[];t=b.createElement(e);t.async=!0;
		t.src=v;s=b.getElementsByTagName(e)[0];
		s.parentNode.insertBefore(t,s)}(window, document,'script',
		'https://connect.facebook.net/en_US/fbevents.js');
		fbq('consent', consent);
		fbq('init', '989222871864976');
		fbq('track', 'PageView');
	</script><script type="module">
		var consent="grant";
		/* The above code is parsing the JSON data from the local storage and storing it in a variable. */</p>
<p>			const onetrustStorageConsent = JSON.parse(localStorage.getItem( 'consent_one_trust_bdc' ) );
			/* Checking to see if the user has consented to the use of cookies.
			* If they have not, it is deleting the cookie.
			* This will comment for now, until further notice.
			*/
			//if ( onetrustStorageConsent.C0002 === false ) {
			//	document.cookie="_fbp=;expires=Thu, 01 Jan 2010 00:00:00 UTC; path=/; domain=.boston.com";
			//}
			/* Checking if the user has given consent for the cookie C0002.
			* If the user has given consent, the variable consent will be set to 'grant'.
			* If the user has not given consent,the variable consent will be set to 'revoke'.
			* Documentation https://developers.facebook.com/docs/meta-pixel/implementation/gdpr
			*/
			if ( ( onetrustStorageConsent !== null ) && (onetrustStorageConsent.C0002 !== true ) ) {
				consent="revoke";
			}</p>
<p>				!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
		{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
		;if(!f._fbq)f._fbq=n;
		n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
		t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
		document,'script','https://connect.facebook.net/en_US/fbevents.js');
		fbq('consent', consent);
		fbq('init', '813236348753005');
		fbq('track', "PageView");
	</script><br />
<br /><em>image credit : www.boston.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://bdc2020.o0bc.com/wp-content/uploads/2024/12/AP24343438170623-6755c7080415d-768x432.jpg" medium="image"></media:content>
	</item>
		<item>
		<title>Moderna posts surprise profit as Covid vaccine sales are impressive and price cuts take hold</title>
		<link>https://bloggingthree.soflytech.com/2024/11/moderna-posts-surprise-profit-as-covid-vaccine-sales-are-impressive-and-price-cuts-take-hold/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sat, 09 Nov 2024 21:46:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cuts]]></category>
		<category><![CDATA[hold]]></category>
		<category><![CDATA[impressive]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[posts]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[surprise]]></category>
		<category><![CDATA[vaccine]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18854</guid>

					<description><![CDATA[Modern reported a surprise third-quarter profit on Thursday, beating Wall Street estimates, as its cost-cutting efforts took effect and sales of its Covid vaccine got here in higher than expected. The biotech company reported net income of $13 million, or 3 cents per share. That compares with a net lack of $3.63 billion, or 9.53 [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-108059513">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-108059513" class="PlaceHolder-wrapper" data-vilynx-id="7000357258" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/108059514-17309817081730981704-37014639197-1080pnbcnews.jpg?v=1730981706&#038;w=750&#038;h=422&#038;vtcrop=y" alt="Moderna posts surprise profit as Covid vaccine sales are impressive and cost cuts take hold"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Modern<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    reported a surprise third-quarter profit on Thursday, beating Wall Street estimates, as its cost-cutting efforts took effect and sales of its Covid vaccine got here in higher than expected. </p>
<p>The biotech company reported net income of $13 million, or 3 cents per share. That compares with a net lack of $3.63 billion, or 9.53 cents per share, reported within the year-earlier period.</p>
<p>Moderna shares were flat on Thursday.</p>
<p>Moderna is dramatically cutting expenses and recently announced a goal of $1.1 billion in savings by 2027 because it tries to get better from the rapid decline of its Covid business. It&#39;s the primary quarter that features sales of Moderna&#39;s respiratory syncytial virus (RSV) vaccine, its second ever commercially available product. </p>
<p>Before the top of the yr, the corporate plans to use for approval of its experimental Covid vaccine and the “next generation” combination vaccination against Covid and the flu. Moderna also expects to use for expanded approval of its RSV vaccine this yr, aimed toward high-risk adults ages 18 to 59. </p>
<p>Moderna said on Thursday that its latest Covid vaccine had advantages after it received approval within the US three weeks sooner than the last iteration of the vaccine in 2023, allowing the biotech company to “meet demand more effectively “. The company was able to ship doses to pharmacies and healthcare providers and reach more patients&#39; arms sooner. </p>
<p>“I think the earlier start and a steeper ramp led to much higher sales of the Covid vaccine,” Moderna CEO Stéphane Bancel said in an interview. In the primary week of the vaccine rollout, the corporate shipped twice as many products worldwide because it did in 2023, Bancel noted. </p>
<p>He added: &#8220;This has been a quarter of major cost cutting and we will continue to do so.&#8221; </p>
<p>Here&#39;s something <a href="https://investors.modernatx.com/news/news-details/2024/Moderna-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" target="_blank" rel="noopener">Moderna reported for the third quarter</a> in comparison with Wall Street expectations based on an analyst survey by LSEG:</p>
<ul>
<li><strong>Earnings per share:</strong> 3 cents versus an expected lack of $1.90</li>
<li><strong>Revenue:</strong> $1.86 billion versus expected $1.25 billion</li>
</ul>
<p>Moderna posted third-quarter sales of $1.86 billion, only barely higher than its $1.83 billion in the identical period last yr. The overwhelming majority of that total got here from Covid vaccinations, including $1.2 billion in U.S. sales and about $600 million in international markets. </p>
<p>The company&#39;s third-quarter sales also included $10 million in U.S. sales of its RSV shot, which received approval in May. Moderna said sales of that vaccine were lower than expected since it was not approved and really useful by regulators until later within the contracting season, when many vaccine distributors had already accomplished their orders. </p>
<p>Analysts had expected sales of $132 million for the RSV vaccine, in accordance with StreetAccount estimates. Moderna&#39;s RSV shot is to date approved within the United States, the European Union, Norway, Iceland and Qatar. </p>
<p>The company reiterated its full-year 2024 product sales guidance of roughly $3 billion to $3.5 billion. In probably the most recent quarter, Moderna lowered its guidance as a consequence of lower expected sales in Europe, a &#8220;competitive environment&#8221; for respiratory vaccines within the U.S. and the potential for deferred international revenue into 2025. </p>
<p>Moderna shares have fallen nearly 50% this yr as investors ponder the trail ahead post-Covid. The company is betting on a pipeline based on its messenger RNA platform, the technology utilized in its Covid vaccine and RSV shot. </p>
<p>The biotech company currently has 45 products in development and expects to bring ten of them to market in the subsequent three years. </p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More CNBC Health coverage</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>Moderna is developing, amongst other things, an independent flu vaccination, a personalised cancer vaccine with Merck and vaccinations against latent viruses.</p>
<p>Third-quarter cost of sales was $514 million, down 77% from the identical period last yr. This includes, amongst other things, write-downs on unused doses of the Covid vaccine of $214 million and charges of $27 million related to the corporate&#39;s efforts to downsize its production site. </p>
<p>Research and development costs fell 2% to $1.1 billion in comparison with the identical period in 2023. Moderna said the decline was primarily as a consequence of lower clinical development and manufacturing spending, citing lower clinical trial spending, amongst other aspects.</p>
<p>Meanwhile, selling, general and administrative expenses fell 36% to $281 million within the period in comparison with the third quarter of 2023. SG&#038;A expenses typically include the prices of promoting, selling, and providing an organization&#39;s services and products.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these insights from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107261602-1687528287269-gettyimages-1237207850-AFP_9UK73T.jpeg?v=1730983924&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Jim Cramer: Abbott shares are &#039;dirt low cost&#039; after surprise court victory confirms our belief</title>
		<link>https://bloggingthree.soflytech.com/2024/11/jim-cramer-abbott-shares-are-dirt-low-cost-after-surprise-court-victory-confirms-our-belief/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Fri, 01 Nov 2024 21:19:29 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[39dirt]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[belief]]></category>
		<category><![CDATA[cheap39]]></category>
		<category><![CDATA[confirms]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Cramer]]></category>
		<category><![CDATA[Jim]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[surprise]]></category>
		<category><![CDATA[Victory]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18381</guid>

					<description><![CDATA[Shares of Abbott Laboratories jumped on Friday after the club holding company scored a surprise victory in a test over the protection of its formula for premature babies. The news that Abbott Labs&#39; special formula was not chargeable for causing a young boy to develop a serious intestinal disease generally known as necrotizing enterocolitis (NEC) [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">Shares of Abbott Laboratories jumped on Friday after the club holding company scored a surprise victory in a test over the protection of its formula for premature babies. The news that Abbott Labs&#39; special formula was not chargeable for causing a young boy to develop a serious intestinal disease generally known as necrotizing enterocolitis (NEC) was revealed by a Missouri state court jury Thursday evening &#8211; concluding a roughly five-week trial , which was closely watched by investors . The jury also cleared Mead Johnson, a subsidiary of Reckitt Benckiser, and St. Louis Children&#39;s Hospital of liability within the case. The plaintiffs had argued that Abbott and Mead Johnson&#39;s formulas &#8211; used to treat premature babies in neonatal intensive care units &#8211; increased the chance of developing NEC and that the businesses didn&#8217;t properly disclose that risk. Abbott and Mead Johnson, for his or her part, strongly deny the allegations and defend the products as medically vital treatments for babies in certain cases where breast milk can&#8217;t be used. “We are pleased with the jury’s decision,” Abbott spokesman Scott Stoffel said in an announcement to CNBC Friday morning. “The decision confirms what we, the medical community and regulators have said: that preterm formula products are safe and there is no reliable scientific evidence that they cause or contribute to causing NEC. Abbott stands by the critical role of its premature infant formula.” and breast milk boosters are utilized in hospital to feed premature infants.” ABT YTD Mountain Abbott Laboratories&#39; stock performance because the starting of the 12 months. Big picture Investors were nervous ahead of Thursday night&#39;s ruling because each firms had lost similar cases this 12 months &#8211; Mead Johnson in March, followed by Abbott Labs in late July. In particular, Mead&#39;s defeat in March brought the NEC issue into sharper focus and triggered a pointy and sustained sell-off in each firms&#39; shares. We purchased additional shares of Abbott Labs on several occasions in the course of the downtrend because we believed that the magnitude of the decline in market value didn&#8217;t adequately reflect the potential damages the corporate would must pay if its litigation went badly despite the medical community on its side . That includes three major U.S. health agencies that issued an announcement last month supporting specialty infant formulas like Abbott&#39;s. The legal overhang at Abbott Labs has been real, at the same time as shares have found some traction in recent months. By Thursday&#39;s close, the stock was up about 13% from its 2024 low set on July 18. Abbott&#39;s highest closing price of the 12 months of $120.96 per share got here on March 8 &#8211; before NEC fears became prevalent. Based on Friday&#39;s premarket earnings, the stock was on the right track to approach those levels. Bottom line: Abbott Labs continues to be facing other cases across the country over its specialty formulas, but Thursday night&#39;s victory is important. This can also be shown by the share response, which rose by greater than 4.5%. “They won a case they were imagined to lose. &#8230; The day for plaintiffs to take the matter to Abbott is over,&#8221; Jim Cramer said on CNBC Friday. “This stock is dirt cheap,” he added. According to FactSet, Abbott shares traded at about 22 times expected earnings estimates on Friday, below their five-year average of 24. One reason this win is such a big deal: The venue for this case was widely considered plaintiff-friendly, Cramer has repeatedly noted that the case that Abbott Labs lost in July was also heard in Missouri state court. Those concerns intensified during the trial in October, when the judge did not allow the jury to see an updated statement from U.S. health authorities. “There is no conclusive evidence that preterm formula causes NEC,” the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health wrote in an October statement. We announced at the time that this statement was a victory for Abbott, but had to temper our expectations after the judge made his decision. Still, we expected that Abbott Labs might lose this case, but at least since the trials began in other states, the company would most likely be able to use the supportive opinion from the FDA, CDC, and NIH to support its defense . With victory in hand, Abbott Labs will now begin the next phase of its legal battle on much stronger ground. The hope is that the conversation about Abbott Labs ultimately focuses entirely on the attractive fundamentals laid out in its third-quarter earnings report last month. If that happens, healthcare investors should like what they hear. (Jim Cramer&#39;s Charitable Trust is long ABT. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation&#39;s portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Abbott Laboratories<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    Shares jumped on Friday after Club Holding won a surprise victory in a test over the protection of its infant formula for premature babies.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108012396-1722007367979-gettyimages-1242016951-BIZ-ABBOTT-LABS-EARNS-TB.jpeg?v=1730465693&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>The Warriors&#039; wing reacts to Steve Kerr&#039;s surprise</title>
		<link>https://bloggingthree.soflytech.com/2024/10/the-warriors-wing-reacts-to-steve-kerrs-surprise/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 30 Oct 2024 04:24:49 +0000</pubDate>
				<category><![CDATA[Sports]]></category>
		<category><![CDATA[Kerr39s]]></category>
		<category><![CDATA[reacts]]></category>
		<category><![CDATA[Steve]]></category>
		<category><![CDATA[surprise]]></category>
		<category><![CDATA[Warriors39]]></category>
		<category><![CDATA[wing]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18221</guid>

					<description><![CDATA[SAN FRANCISCO — Sixty-five minutes before game time, Jonathan Kuminga stood at his locker after pregame sprints across the ground of the Warriors&#39; practice room at Chase Center. While he was warming up, ESPN reported that the Warriors would bring him off the bench although Steph Curry, Andrew Wiggins and De&#39;Anthony Melton were unavailable. Kuminga [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2024/04/BNG-L-WARRIORS-0418-97.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p>SAN FRANCISCO — Sixty-five minutes before game time, Jonathan Kuminga stood at his locker after pregame sprints across the ground of the Warriors&#39; practice room at Chase Center. While he was warming up, ESPN reported that the Warriors would bring him off the bench although Steph Curry, Andrew Wiggins and De&#39;Anthony Melton were unavailable.</p>
<p>Kuminga said he had not yet personally spoken to Steve Kerr in regards to the decision.</p>
<p>“It’s his decision,” Kuminga said. “I am not the coach. When Steve has made his decision, he has made his decision. I’m not the coach.”</p>
<p>Kuminga said he&#39;s &#8220;not upset&#8221; about coming off the bench, but that there may be growing skepticism in Kuminga&#39;s camp about Kerr&#39;s commitment to using the wing in Golden State&#39;s offense.</p>
<p>Just three games into the season, after Kuminga&#39;s camp and the Warriors failed to succeed in an agreement on a rookie extension, tensions are simmering between the 2 teams.</p>
<p>Negotiations between the Warriors and Kuminga never got off to a serious start before the rookie extension deadline. The Warriors valued the in-season flexibility that may have been lost in the event that they had prolonged Kuminga. Kuminga&#39;s camp was not adamant in regards to the maximum contract, but never received offers that they considered fair market value, in accordance with sources.</p>
<p>On Tuesday night, Kerr declined to announce a starting lineup in his pregame press conference. When asked directly whether Kuminga would start, he replied: “Possibly.”</p>
<p>Kerr then didn&#39;t need to answer questions on his starting lineup of Brandin Podziemski, Buddy Hield, Moses Moody, Draymond Green and Trayce Jackson-Davis before the sport. It appears the Warriors prioritized Moody&#39;s 3-point shooting over Kuminga&#39;s downhill threat and maintained the continuity of Green and Jackson-Davis.</p>
<p>The decision to take Kuminga off the bench against New Orleans is a surprising decision by the coaching staff. With Curry, Wiggins and Melton each out as a result of injury, the sport changed into one by which the Warriors had to make use of Kuminga heavily on offense. He averaged 16.1 points per game last season and is arguably Golden State&#39;s most talented scorer.</p>
<aside class="related left"></aside>
<p>However, Kuminga struggled to start out the season. In the primary three games of the season, he averaged 8.0 points and three.3 rebounds in 19.7 minutes per game. The big lineup with Kuminga as a small forward alongside two non-shooting bigs hasn&#39;t complemented his game yet, and the 12-man rotation Kerr uses has reduced his minutes.</p>
<p>“I never worry about such a small sample size,” Kerr said of Kuminga. “JK had a really good preseason, he will do it. We&#39;re going to need his strength, his athleticism. Tonight could be a big night for him in that regard, depending on how the game turns out. Of course, we played against twelve players in every game, which means it will be a little more difficult for each player to find their rhythm because they don&#39;t play as much. I&#39;m not worried about JK at all. He’ll come over.”</p>
<p>Kuminga professionally answered questions at his locker before the sport, reiterating that he was not the coach and the choice was out of his hands. When asked whether he would like to start out or come off the bench, he said he was just here to play; He began 46 of 74 games last yr.</p>
<p>He also described the beginning to his season as “decent”.</p>
<p>“You’re not just going to come out of the gate and be perfect every time,” Kuminga said. “You try to figure things out, meet new people, the way we play. Different attack, different sets. So I just have to figure it out.”</p>
<p>The relationship between Kerr and Kuminga is a feast for the eyes. Last season, after Kerr benched Kuminga for the ultimate 18 minutes of a loss to Denver, <a href="https://www.nytimes.com/athletic/5181608/2024/01/05/jonathan-kuminga-steve-kerr-warriors-lineup/" target="_blank" rel="noopener">The Athletic reported</a> that Kuminga had “lost trust” in his coach.</p>
<p>Now, lower than per week into the season, the 2 have rather a lot to sort out.</p>
<p>“I’m used to it – this is my fourth year,” Kuminga said. “This is not the first time something like this has happened. As I said, I&#39;m not the coach, that&#39;s his decision. We will follow his decision.”</p>
</p></div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/04/BNG-L-WARRIORS-0418-97.jpg?w=1024&#038;h=742" medium="image"></media:content>
	</item>
		<item>
		<title>It&#039;s no surprise that Amazon shares are falling after the cloud CEO&#039;s restructuring</title>
		<link>https://bloggingthree.soflytech.com/2024/05/its-no-surprise-that-amazon-shares-are-falling-after-the-cloud-ceos-restructuring/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Tue, 21 May 2024 08:29:59 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Amazon]]></category>
		<category><![CDATA[CEO39s]]></category>
		<category><![CDATA[cloud]]></category>
		<category><![CDATA[falling]]></category>
		<category><![CDATA[It39s]]></category>
		<category><![CDATA[restructuring]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[surprise]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=4070</guid>

					<description><![CDATA[Every weekday, CNBC Investing Club hosts a “Morning Meeting” livestream with Jim Cramer at 10:20 a.m. ET. Here&#39;s a recap of Tuesday&#39;s key moments. U.S. stocks were little modified on Tuesday because the market digested hotter-than-expected inflation data. April&#39;s producer price index got here in above estimates, further complicating the Federal Reserve&#39;s rate cut schedule. [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<div data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2">
<p><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">Every weekday, CNBC Investing Club hosts a “Morning Meeting” livestream with Jim Cramer at 10:20 a.m. ET.  Here&#39;s a recap of Tuesday&#39;s key moments.  U.S. stocks were little modified on Tuesday because the market digested hotter-than-expected inflation data.  April&#39;s producer price index got here in above estimates, further complicating the Federal Reserve&#39;s rate cut schedule.  However, Jim Cramer argued that a negative revision to the March PPI offset price pressures in Tuesday&#39;s release.  The club pays attention to the patron price index on Wednesday, which is more essential for understanding the final inflation trend.  Elsewhere, the return of meme stocks like GameStop is an enormous topic on Wall Street.  Members should avoid getting involved within the madness because it is going to definitely end as badly because it did three years ago.  Shares of Danaher rose nearly 2% on Tuesday.  But you shouldn&#39;t sell a life sciences company&#39;s shares based on strength, Jim argued, suggesting that recent momentum could prompt some investors to revisit the stock.  “You don’t sell a stock that’s finally moving,” he said.  &#8220;It&#39;s stuck in the mud and people like it now.&#8221; The long-awaited turnaround in biotech industry funding and enhancements in customer inventories were evident in Danaher&#39;s earnings report last month, which sent shares up 7, 2% in a single session.  We&#39;ll be waiting for updated comments from management at a Bank of America healthcare conference afterward Tuesday.  The stock has now risen by greater than 10% for the reason that starting of the yr.  Amazon announced Tuesday that Amazon Web Services CEO Adam Selipsky will step down in June.  Selipsky will leave Amazon&#39;s cloud computing business in a powerful position as first-quarter revenue rose 17% yr over yr.  Shares of the club holding company fell about 0.5% on Tuesday.  “He did a remarkable job,” Jim said.  &#8220;I understand why [the stock] is down because he&#39;s a titan.&#8221; Matt Garman, an 18-year company veteran who currently serves as senior vp of sales and marketing at AWS, is predicted to switch Selipsky.  (Jim Cramer&#39;s Charitable Trust has long been DHR, AMZN. See here (A full list of stocks will be found here.) As a subscriber to CNBC Investing Club with Jim Cramer, you&#8217;ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock If Jim has discussed a stock on CNBC television, he&#8217;ll wait 72 hours after the trade alert is issued before executing the trade. THE ABOVE INVESTMENT CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , ALONG WITH OUR DISCLAIMER, THERE ARE NO FIDUCTIVE OBLIGATIONS OR OBLIGATIONS IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107171874-1672252536649-gettyimages-1236309559-HCASINHAS_02112021_WEBSUMMIT-017.jpeg?v=1715703822&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Mason Lohrei&#039;s playoff stance is not any surprise to the Bruins captain</title>
		<link>https://bloggingthree.soflytech.com/2024/04/mason-lohreis-playoff-stance-is-not-any-surprise-to-the-bruins-captain/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Mon, 29 Apr 2024 05:19:37 +0000</pubDate>
				<category><![CDATA[Sports]]></category>
		<category><![CDATA[Bruins]]></category>
		<category><![CDATA[captain]]></category>
		<category><![CDATA[Lohrei39s]]></category>
		<category><![CDATA[Mason]]></category>
		<category><![CDATA[playoff]]></category>
		<category><![CDATA[stance]]></category>
		<category><![CDATA[surprise]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=1946</guid>

					<description><![CDATA[Bruins Brad Marchand has a whopping 150 playoff games under his belt. With his one-timer faltering Saturday night, Boston&#39;s captain lit the lamp 56 times through the Stanley Cup playoffs. No Bruins player has scored more goals within the postseason. Experience is a prized commodity through the Stanley Cup Playoffs. Teams place a high value [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="">
<header class="m-article-header m-article-header--standard">
												<span id="article-header-primary-term"></p>
<p>								Bruins<br />
							</span></p>
</header>
<p>Brad Marchand has a whopping 150 playoff games under his belt. </p>
<p>With his one-timer faltering Saturday night, Boston&#39;s captain lit the lamp 56 times through the Stanley Cup playoffs.  No Bruins player has scored more goals within the postseason. </p>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"></figure>
<p>Experience is a prized commodity through the Stanley Cup Playoffs.  Teams place a high value on seasoned veterans who&#8217;ve already endured the physical and mental rigor required to secure hockey&#39;s most coveted prize. </p>
<p>But for all his accolades at hockey&#39;s highest stage, Marchand doesn&#39;t all the time imagine experience is the deciding factor relating to delivering within the playoffs. </p>
<p>Because when the 35-year-old Marchand won the Stanley Cup in 2011, he was a 23-year-old rookie &#8211; unencumbered by the pressure that understandably builds over time as NHL players push for a coveted title. </p>
<p>Thirteen years later, Boston&#39;s elder statesmen see one other Bruins rookie following the same script during playoff motion in 23-year-old defenseman Mason Lohrei. </p>
<p>&#8220;I remember my first run, it&#39;s pure adrenaline,&#8221; Marchand said after Boston&#39;s 3-1 win over the Maple Leafs in Game 4. &#8220;You go out there and you&#39;re so excited that you finally have the opportunity to do it.&#8221; You&#39;ve worked and played this game your whole life, and the hours and time you&#39;ve put in gives you a likelihood to play for the Stanley Cup. </p>
<p>“And that’s right in front of you.  And it&#39;s just pure adrenaline.  &#8230; Mason came in and played incredible for us.  He made a lot of really good plays and jumped up in the game.  He fights hard and plays strong defensively.  So it’s great to see.” </p>
<p>Forced into the playoffs after an injury to Andrew Peeke and a scratch to Matt Grzelcyk, Lohrei played a key role in Boston&#39;s win on Saturday &#8211; he was a key helper on James van Riemsdyk&#39;s opening tally and logged 17:36 of ice time. </p>
<p>&#8220;How assertive he was,&#8221; Jim Montgomery said Sunday about what stood out about Lohrei&#39;s play in Game 4.  “I mean, he was so good last night.  With the puck, without the puck, he was all over the ice making plays and obviously he was a big part of why we won.”</p>
<p>It doesn&#39;t take long to know why Lohrei is taken into account Boston&#39;s top player in its potential pipeline. </p>
<p>His shot-first approach and playmaking attitude as a defenseman is probably not a whole outlier in today&#39;s skill-critical NHL.  But few D-men can hit the bottom running and produce Grade-A looks while also boasting a sturdy 6-foot-1, 220-pound frame that ought to only increase over time. </p>
<p>After a quieter performance in Game 3 at Scotiabank Arena, Lohrei made a direct impact in the primary period of Saturday&#39;s win. </p>
<p>A heads-up play from the rookie arrange Boston&#39;s first goal as Lohrei made a save from the offensive blue line as Toronto stickman Ryan Reaves attempted to direct a puck over the boards. </p>
<p>Lohrei&#39;s pin caused Reaves to hurl the puck under duress, leading to a turnover on Class A ice, which van Riemsdyk promptly slipped past Ilya Samsonov and put Boston on the board at 15:09 of the primary period. </p>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter">
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">James van Riemsdyk scores his first goal since February.  17.</p>
<p>Brutal rally by the Leafs and JVR beats Samsonov by five.</p>
<p>1-0 Bruins. <a href="https://t.co/XNZ0BxoLvT">pic.twitter.com/XNZ0BxoLvT</a></p>
<p>— Conor Ryan (@ConorRyan_93) <a href="https://twitter.com/ConorRyan_93/status/1784383611279405175?ref_src=twsrc%5Etfw">April 28, 2024</a></p></blockquote>
</div>
</figure>
<p>It was an exhilarating move from Boston&#39;s young defender, whose confidence had been demonstrated earlier within the period when he attempted to beat Samsonov with a deft between-the-legs effort at 4-on-4. </p>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"></figure>
<p>Lohrei&#39;s creativity with the puck on his stick is welcome within the postseason.  But to remain within the lineup, he must proceed to make the correct plays, avoid turnovers against forechecking pressure and limit the number of excellent probabilities in front of Jeremy Swayman and Linus Ullmark.</p>
<p>But after two games, the rookie appears to be as much as the duty.</p>
<p>“This time of year you have to belong and want to make a difference,” Marchand said.  “And that’s what we seem to have in the group right now.  &#8230;Him and Johnny (Beecher) and Parker (Wotherspoon) were unbelievable for us.  And I think that’s just because they go out and play and have that belief in themselves.” </p>
<h3 class="wp-block-heading" id="h-forbort-getting-closer"><strong>Forbort comes closer</strong></h3>
<p>Derek Forbort was not cleared for Games 3 and 4 in Toronto this week, however the 32-year-old defenseman took part within the warmups that led to Saturday&#39;s win. </p>
<p>Montgomery indicated the team will evaluate Forbort&#39;s availability for Game 5 after practice on Monday.  But his participation in warmups marked one other box for Forbort in his recovery from surgery in March. </p>
<p>“It&#39;s about getting him into the routine in case he becomes an option,” Montgomery said of Forbort&#39;s performance during warmups.  “Get used to the routine of how you prepare for the game and all those things.  Engaging with your teammates, listening to the locker room – all of that is important to your preparation if you become an option down the road.”</p>
<p>Any clues about Boston&#39;s starting goaltender in Game 5? </p>
<p>“Find out Tuesday night,” Montgomery remarked. </p>
<h3 class="wp-block-heading" id="h-matthews-still-laboring-with-illness"><strong>Matthews still suffers from an illness</strong></h3>
<p>Maple Leafs coach Sheldon Keefe didn&#8217;t provide a positive update on Toronto&#39;s star forward Auston Matthews on Sunday.  Matthews didn&#8217;t play within the third period of Game 4 on Saturday because doctors ruled him out of the sport because of illness. </p>
<p>“We thought the last few days would help us” <a href="https://www.espn.com/nhl/story/_/id/40044809/maple-leafs-auston-matthews-feeling-effects-illness" target="_blank" rel="noreferrer noopener">Keefe told reporters in Toronto on Sunday. </a>“But for some reason it’s not one of those everyday illnesses that come and go.  This one has lingered and the effects have lingered and are getting worse when he is on the ice and asserting himself.”</p>
<p>Matthews was one of the best player on the ice for Toronto through the Leafs&#39; Game 2 win at TD Garden &#8211; he scored a goal and two major assists over 23:24 of ice time while recording eight shots on goal, a team-high six goals and&#8230; 16 of 23 Faceoffs won.</p>
<p>But Matthews was unable to hold this game through in Games 3 and 4 as he scored zero points with a complete of 4 shots on goal in each losses. </p>
<div class="m-block m-generic-cta
	 m-generic-cta--post-content	 m-generic-cta--dark	 m-generic-cta--homepage	 m-generic-cta--email-signup		 m-generic-cta-block-style--default 
	t-amp__generic-cta"></p>
</div></div>
<p><script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script><script>
		var consent="grant";
		/* The above code is parsing the JSON data from the local storage and storing it in a variable. */
					const onetrustStorageConsent = JSON.parse(localStorage.getItem( 'consent_one_trust_bdc' ) );
			if ( ( onetrustStorageConsent !== null ) ) {
				/* Checking to see if the user has consented to the use of cookies.
				* If they have not, it is deleting the cookie.
				* This will comment for now, until further notice.
				*/
				//if ( onetrustStorageConsent.C0002 === false ) {
				//	document.cookie="_fbp=;expires=Thu, 01 Jan 2010 00:00:00 UTC; path=/; domain=.boston.com";
				//}
				/* Checking if the user has given consent for the cookie C0002.
				* If the user has given consent, the variable consent will be set to 'grant'.
				* If the user has not given consent,the variable consent will be set to 'revoke'.
				* Documentation https://developers.facebook.com/docs/meta-pixel/implementation/gdpr
				*/
				if ( onetrustStorageConsent.C0002 !== true ) {
					consent="revoke";
				}
			}
				!function(f,b,e,v,n,t,s)
		{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
		n.callMethod.apply(n,arguments):n.queue.push(arguments)};
		if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
		n.queue=[];t=b.createElement(e);t.async=!0;
		t.src=v;s=b.getElementsByTagName(e)[0];
		s.parentNode.insertBefore(t,s)}(window, document,'script',
		'https://connect.facebook.net/en_US/fbevents.js');
		fbq('consent', consent);
		fbq('init', '989222871864976');
		fbq('track', 'PageView');
	</script><script type="module">
		var consent="grant";
		/* The above code is parsing the JSON data from the local storage and storing it in a variable. */</p>
<p>			const onetrustStorageConsent = JSON.parse(localStorage.getItem( 'consent_one_trust_bdc' ) );
			/* Checking to see if the user has consented to the use of cookies.
			* If they have not, it is deleting the cookie.
			* This will comment for now, until further notice.
			*/
			//if ( onetrustStorageConsent.C0002 === false ) {
			//	document.cookie="_fbp=;expires=Thu, 01 Jan 2010 00:00:00 UTC; path=/; domain=.boston.com";
			//}
			/* Checking if the user has given consent for the cookie C0002.
			* If the user has given consent, the variable consent will be set to 'grant'.
			* If the user has not given consent,the variable consent will be set to 'revoke'.
			* Documentation https://developers.facebook.com/docs/meta-pixel/implementation/gdpr
			*/
			if ( ( onetrustStorageConsent !== null ) && (onetrustStorageConsent.C0002 !== true ) ) {
				consent="revoke";
			}</p>
<p>				!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
		{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
		;if(!f._fbq)f._fbq=n;
		n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
		t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
		document,'script','https://connect.facebook.net/en_US/fbevents.js');
		fbq('consent', consent);
		fbq('init', '813236348753005');
		fbq('track', "PageView");
	</script><br />
<br /><em>image credit : www.boston.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://bdc2020.o0bc.com/wp-content/uploads/2024/04/Bruins_Maple_Leafs_Hockey_20409-662eac0b9d424-768x432.jpg" medium="image"></media:content>
	</item>
		<item>
		<title>Abbott Labs&#039; surprise improvement in guidance is a giant positive for shareholders</title>
		<link>https://bloggingthree.soflytech.com/2024/04/abbott-labs-surprise-improvement-in-guidance-is-a-giant-positive-for-shareholders/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sun, 21 Apr 2024 06:50:31 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[guidance]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[Labs39]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[surprise]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=1096</guid>

					<description><![CDATA[Abbott Laboratories posted above-average sales and profit on Wednesday and surprised investors by raising its full-year forecast, a vote of confidence from the medical device maker not seen in a primary quarter since 2016. Revenue rose barely more within the three months ended March 31. LSEG said revenue rose greater than 2% 12 months over [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">Abbott Laboratories posted above-average sales and profit on Wednesday and surprised investors by raising its full-year forecast, a vote of confidence from the medical device maker not seen in a primary quarter since 2016.  Revenue rose barely more within the three months ended March 31. LSEG said revenue rose greater than 2% 12 months over 12 months to $9.96 billion, beating expectations of $9.88 billion.  On an organic basis, sales increased by 10.8% in comparison with the identical period last 12 months (excluding Covid test sales), also exceeding expectations for a rise of 9.45%.  Earnings per share fell a bit of lower than 5% to 98 cents, beating the Street&#39;s estimate of 95 cents.  Abbott Laboratories Why we own the corporate: Abbott is a high-quality medical technology company that&#8217;s growing rapidly.  The stock is grappling with two headwinds: declining sales of Covid tests and concerns that the introduction of GLP-1 will disrupt its flagship continuous glucose monitor.  As Abbott&#39;s organic sales growth continues to shine, the market will realize that each concerns are overblown.  Competitors: Dexcom and Edwards Lifesciences.  Weight within the club portfolio: 2.71%.  Last Purchased: April 4, 2024. Initiated: January 29, 2024. Bottom line, Abbott shares fell on Wednesday following a solid report, likely resulting from minor segment misses in addition to a slight decline in current-quarter earnings guidance the expectations.  However, investors are specializing in the improper thing and may as an alternative welcome the upward revision to the full-year forecast.  For a management team that prefers to depart its forecasts unchanged in its first-quarter reports, this was a giant positive for investors.  We&#39;re also pleased that Tuesday&#39;s EPS results got here in above management&#39;s forecast range &#8211; a classic case of under-promising and over-delivering.  ABT YTD Mountain Abbott Laboratories YTD organic growth was very strong at nearly 11%, marking the fifth consecutive quarter of double-digit gains.  Additionally, each adjusted gross margin and pre-tax profit margin exceeded expectations.  The growth of FreeStyle Libre, the corporate&#39;s popular glucose monitoring system, has been impressive and is anticipated to proceed as European coverage expands.  Despite all of those positives, the stock is down about $1, or nearly 1%, this 12 months.  We decided to step on this morning and benefit from the weakness by selling 100 shares.  The charitable trust now owns 800 shares of ABT, representing about 2.8% of the portfolio.  We reiterate our 1 rating on ABT stock and our $130 price goal.  Guidance For the total 12 months, management now expects organic revenue growth (excluding Covid testing) within the range of 8.5% to 10%, up from the previous range of 8% to 10% and above the Street estimate of 8.9 %.  Management also raised the midpoint of its EPS forecast to $4.55 to $4.70, up from the previous range of $4.50 to $4.70 and a penny above the common of $4.59 on the road.  This implies an excellent outlook for the remaining of the 12 months.  CEO Robert Ford said on the earnings call with investors that growth is accelerating in a lot of Abbott&#39;s businesses.  That greater than makes up for the present quarter&#39;s miss: Abbott expects second-quarter earnings to fall to $1.08 to $1.12 per share, below the Street&#39;s median estimate of $1.12 -Dollar lies.  Baby Formula Lawsuit Management reiterated its stance that allegations that the newborn formula may cause necrotizing enterocolitis (NEC) in infants are unfounded.  CEO Ford said that experts within the medical community &#8220;view these products as critical, a critical part of the standard of care for the nutrition of premature infants,&#8221; he said, adding that &#8220;the physicians who work in neonatal intensive care units use our products “In other words, the team stands behind their product.  We do not take the situation lightly.  NEC is terrible and we recognize the overhang this news has created.  However, the pressure on the first quarter results is exaggerated.  As we can see in the chart above, the medical devices segment was the driver of Q1 results, more than offsetting some weaknesses in nutrition, diagnostics and established pharmaceuticals &#8211; although the misses were minor. Notably, all of them Important sub-segments of medical devices (rhythm management, electrophysiology, heart failure, vascular care, structural heart treatment, neuromodulation and diabetes care) also exceeded expectations.  FreeStyle Libre&#39;s revenue reached $1.5 billion, up 23% year-over-year &#8211; growth is expected to continue as reimbursement coverage increases in the European market.  In the nutrition business, a failure in the adult category more than negated strength in pediatrics.  However, the company has high hopes for Protality, the company&#39;s newest nutritional formula for adults taking GLP-1 drugs.  “When people eat less and lose weight because they take GLP-1 drugs, have weight loss surgery, or follow a calorie-restricted diet, some of that is lost, muscle mass, which plays an important role in overall health,” said he Ford added that Protality can help people maintain muscle while losing weight.  In addition, management highlighted the recent FDA approval of its i-STAT TBI (traumatic brain injury) cassette, which can help determine whether someone has suffered a mild traumatic brain injury or concussion in just 15 minutes, making it an attractive option Growth opportunity.  Nearly 5 million people go to the emergency room every year for traumatic brain injury and more than half of those suspecting a concussion increased organically by 14.3% from established pharmaceuticals (up 13.7%) and nutrition (up 7 .7%).  In diagnostics, where we are seeing the impact of the decline in Covid testing sales, organic sales rose 5.4% year-over-year. Sales in &#8220;emerging markets&#8221; &#8211; Abbott defines the emerging markets that offer the most attractive long-term growth opportunities &#8211; increased organically by 15.4%.  (Jim Cramer&#39;s Charitable Trust is long ABT. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.  Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation&#39;s portfolio.  If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade.  THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER.  THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB.  NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Abbott Laboratories<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    posted above-average sales and profit on Wednesday and surprised investors by raising its full-year forecast, a vote of confidence from the medical device maker not seen in any first quarter since 2016.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/106822918-1610458806047-abbott_workplace_testing_L9931.jpg?v=1620766163&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
